<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01346475</url>
  </required_header>
  <id_info>
    <org_study_id>30520-D - Phase 2</org_study_id>
    <nct_id>NCT01346475</nct_id>
  </id_info>
  <brief_title>Randomized Trial to Evaluate Suppressive Effect of High-Dose Valacyclovir Versus Once-Daily Valacyclovir on Persons With HSV-2</brief_title>
  <official_title>A Randomized, Cross-Over Study to Evaluate the Suppressive Effect of High-Dose Valacyclovir Versus Once Daily Valacyclovir on Herpes Simplex Virus Type 2 Genital Shedding in Herpes Simplex Virus-2 Seropositive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      On 13 August 2008, this trial was submitted to ClinicalTrials.gov as modification to
      NCT00362297. On 28 April 2011, the two records were split for administrative purposes and
      each trial was given its own unique study record. Please refer to the &quot;History of Changes&quot; on
      posting NCT00362297 for a detailed summary of the modifications.

      The purpose of the research study is to evaluate the effectiveness of high-dose valacyclovir
      compared to once daily valacyclovir for reduction of asymptomatic HSV-2 genital shedding in
      persons with genital herpes.

      The study will enroll men and women who are 18 years or older, test positive to HSV-2 (by
      blood test) and have had a first outbreak of HSV-2 within the past 6 months or have had at
      least 4 genital herpes outbreaks in the past year. Participants must be HIV negative and
      willing to stop taking suppressive therapy for HSV for the one week wash out period. (Females
      only: You must not be pregnant or breast-feeding). Both men and women will be asked to use an
      effective form of birth control.

      Involvement in the study will last 11-weeks and you will be asked to visit the clinic every
      2-weeks. At each visit, you will be given medication to take daily (either once daily
      valacyclovir or high dose valacyclovir; you will receive both medications at some point
      during this study). We will ask you to give a blood sample for liver, kidney and blood count
      testing at each visit. There will be a total of 8 study visits and each visit will last
      approximately 30 minutes. We will ask that you complete a daily symptom diary and collected
      daily home swabs 4-times a day, everyday during the study. Each daily home swab will take
      less than 3 minutes to perform.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening Assessment

      Patients will be assessed for their eligibility to enter the study at a screening visit.
      After signing informed consent they will undergo a medical history and the following
      information will be recorded in the Case Report Form (CRF):

        -  Demographic Data: Date of birth, sex, marital status, education and race

        -  Previous antiviral medication taken

        -  History of sexually transmitted infections and sexual history.

        -  Women of childbearing potential will undergo a urine pregnancy test. Serologic samples
           for HSV-2 and HIV will be obtained. Part of the blood sample will also be used for
           safety labs.

      Start of Study Visit (Day 0) and Day 14, 28, 35, 42, 56, 70, and 77 Follow-Up Visits.

      Eligible patients will return to clinic to be given study drug and a patient diary card on
      which to record concomitant medications, signs and symptoms, and adverse experiences. The
      investigator will instruct the patient on daily home viral sample collection, taking the
      study drug, and completing the diary card. The patient will be instructed to return to clinic
      in 2 weeks, +/- 2 days. Medication compliance will be assessed at each visit using pill
      counts. Safety labs will be performed on day 14, 28, 35, 56, 70 and 77.

      Crossover Study Visit Prior To Washout Period (Day 35-41)

      Participants will not be given study drug or placebo during the 7-day washout period.
      Participants will not be required to obtain swabs during the washout period.

      Daily Home Viral Sample Collection

      Participants will collect swabs from the genital mucosa four times per day and store the
      samples in PCR media with preprinted labels. Women will swab the cervicovaginal, vulvar and
      perianal areas, and men will swab the penile and perianal. Every two weeks, they will return
      the samples to the Virology Research Clinic when they present for additional study drug and
      assessment.

      Final Study Visit (Day 77)

      At the final study visit at Day 77 or for premature discontinuation, the investigator will
      perform the activities at the regular study visits, with the exception of the dispensation of
      study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir as Compared to Once-daily Valacyclovir.</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantity of HSV Detected, Median</measure>
    <time_frame>11 weeks</time_frame>
    <description>Median quantity of HSV detected, among swabs with any HSV detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Genital HSV Shedding Episodes</measure>
    <time_frame>11 weeks</time_frame>
    <description>The number of HSV shedding episodes. A shedding episode is defined as any number of positive swabs preceded and followed by 2 negative swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Genital HSV Shedding Episodes</measure>
    <time_frame>11 weeks</time_frame>
    <description>Median duration of HSV shedding episodes, in hours, among episodes of known duration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Genital Herpes</condition>
  <arm_group>
    <arm_group_label>valacyclovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>high dose valacyclovir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valacyclovir</intervention_name>
    <description>1000 mg orally three times daily for 5 weeks</description>
    <arm_group_label>high dose valacyclovir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valacyclovir</intervention_name>
    <description>500 mg orally once daily for 5 weeks</description>
    <arm_group_label>valacyclovir</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years or older;

          -  HSV-2 seropositive by Western Blot;

          -  not receiving any drugs with known anti-HSV-2 activity for study duration;

          -  history of primary genital herpes infection within past 6 months OR history of 4 or
             more HSV recurrences per year during the past year OR 4 or more recurrences per year
             prior to initiation of suppressive antiviral therapy; or shedding HSV-2 from genital
             mucosa on &gt;25% of days in shedding session performed at the VRC within the last 2
             years.

          -  able to comply with the study protocol;

          -  women of child bearing potential who are sexually active with men must be using a
             medically accepted method of contraception as judged by the investigator;

          -  women of child-bearing potential must have a negative pregnancy test (urine) at
             screening visit;

          -  in general good health, without other serious medical conditions and specifically with
             normal renal and hepatic function, as determined by the patient's medical history;

          -  planning to remain resident in the area of the study center for the duration of the
             study participation;

          -  HIV seronegative.

        Exclusion Criteria:

          -  hypersensitivity to acyclovir or valacyclovir;

          -  pregnant women;

          -  HIV positive or other immunosuppressed state, including chronic steroid use.
             Intermittent nasal or topical steroids are acceptable
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Johnston, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Washington Virology Research Clinic</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2011</study_first_submitted>
  <study_first_submitted_qc>April 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2011</study_first_posted>
  <results_first_submitted>March 23, 2012</results_first_submitted>
  <results_first_submitted_qc>March 6, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 9, 2017</results_first_posted>
  <last_update_submitted>March 6, 2017</last_update_submitted>
  <last_update_submitted_qc>March 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>Christine Johnston</investigator_full_name>
    <investigator_title>Acting Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Herpes Genitalis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valacyclovir</mesh_term>
    <mesh_term>Acyclovir</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants recruited from October 2008 to April 2010. Participants recruited at the University of Washington Virology Research Clinic in Seattle, WA.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Standard-dose Valacyclovir First Then High-dose Valacyclovir</title>
          <description>Standard-dose valacyclovir (500 mg daily) for 5 weeks followed by 1 week wash-out and then high-dose valacyclovir (1 gram three times daily) for 5 weeks</description>
        </group>
        <group group_id="P2">
          <title>High-dose Valacyclovir First Then Standard-dose Valacyclovir</title>
          <description>High-dose valacyclovir (1 gram three times daily) for 5 weeks followed by 1 week wash-out and then standard-dose valacyclovir (500 mg daily) for 5 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valacyclovir</title>
        </group>
        <group group_id="B2">
          <title>High Dose Valacyclovir</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="28"/>
            <count group_id="B3" value="50"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.9" spread="9.5"/>
                    <measurement group_id="B2" value="37.7" spread="12.8"/>
                    <measurement group_id="B3" value="40.4" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir as Compared to Once-daily Valacyclovir.</title>
        <time_frame>11 weeks</time_frame>
        <population>Participants who collected at least one swab on each arm of the cross-over were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard-dose Valacyclovir (500 mg Daily)</title>
          </group>
          <group group_id="O2">
            <title>High-dose Valacyclovir (1 gm Three Times Daily)</title>
          </group>
        </group_list>
        <measure>
          <title>Frequency of HSV-2 Total Shedding From the Genital Tract as Measured by PCR, Calculated Using a Per-day Shedding Rate in Participants Treated With High-dose Valacyclovir as Compared to Once-daily Valacyclovir.</title>
          <population>Participants who collected at least one swab on each arm of the cross-over were included in the analysis.</population>
          <units>percentage of swabs with HSV detected</units>
          <param>Number</param>
          <units_analyzed>Swabs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Swabs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5008"/>
                <count group_id="O2" value="4973"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>This study had 80% power to detect a 50% reduction in HSV genital shedding rates for high-dose valacyclovir compared to standard dose valacyclovir.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Incident risk ratio</method>
            <method_desc>The model is adjusted for period effects.</method_desc>
            <param_type>Incident Risk Ratio</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.44</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quantity of HSV Detected, Median</title>
        <description>Median quantity of HSV detected, among swabs with any HSV detected</description>
        <time_frame>11 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard-dose Valacyclovir (500 mg Daily)</title>
          </group>
          <group group_id="O2">
            <title>High-dose Valacyclovir (1 gm Three Times Daily)</title>
          </group>
        </group_list>
        <measure>
          <title>Quantity of HSV Detected, Median</title>
          <description>Median quantity of HSV detected, among swabs with any HSV detected</description>
          <units>log 10 copies/ml</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>swabs</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>swabs</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="292"/>
                <count group_id="O2" value="164"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.4" upper_limit="4.5"/>
                    <measurement group_id="O2" value="2.5" lower_limit="2.3" upper_limit="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Genital HSV Shedding Episodes</title>
        <description>The number of HSV shedding episodes. A shedding episode is defined as any number of positive swabs preceded and followed by 2 negative swabs.</description>
        <time_frame>11 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard-dose Valacyclovir (500 mg Daily)</title>
          </group>
          <group group_id="O2">
            <title>High-dose Valacyclovir (1 gm Three Times Daily)</title>
          </group>
        </group_list>
        <measure>
          <title>Number of Genital HSV Shedding Episodes</title>
          <description>The number of HSV shedding episodes. A shedding episode is defined as any number of positive swabs preceded and followed by 2 negative swabs.</description>
          <units>Episodes</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Genital HSV Shedding Episodes</title>
        <description>Median duration of HSV shedding episodes, in hours, among episodes of known duration</description>
        <time_frame>11 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard-dose Valacyclovir (500 mg Daily)</title>
          </group>
          <group group_id="O2">
            <title>High-dose Valacyclovir (1 gm Three Times Daily)</title>
          </group>
        </group_list>
        <measure>
          <title>Duration of Genital HSV Shedding Episodes</title>
          <description>Median duration of HSV shedding episodes, in hours, among episodes of known duration</description>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <units_analyzed>Episodes</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="43"/>
                <count group_id="O2" value="43"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Episodes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
                <count group_id="O2" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="7" upper_limit="42"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected for the 11 week study period.</time_frame>
      <desc>Adverse event data was collected on 43 participants who completed the trial. In addition, 1 participant who withdrew during the standard dose valacyclovir arm and 1 participant who withdrew during the high dose valacyclovir arm had adverse events, and these data are included in the total number of AEs and participants included.</desc>
      <group_list>
        <group group_id="E1">
          <title>Valacyclovir</title>
        </group>
        <group group_id="E2">
          <title>High Dose Valacyclovir</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="44"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review and comment on any proposed publication, and all Study results and data reasonably necessary for a meaningful review of the proposed publication are submitted to the sponsor for a period of at least thirty (30) days prior to submitting the publication to any third party.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This trial was performed at a single site and enrolled healthy, mostly white adults with frequent genital herpes outbreaks. Whether these finding are generalizable to other populations is unknown.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Christine Johnston</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-520-4340</phone>
      <email>cjohnsto@u.washington.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

